Últimas noticias sobre Quantum-Si (NASDAQ:QSI) Bolsa

Quantum-Si

Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.

Pre-Market Outlook

Markets

Movers

ACON

AEON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

LDTC

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Explora los mayores movimientos en el premercado con ganancias superiores al 100% y pérdidas significativas antes de la apertura.

Acciones de Smart Share Global se disparan un 44%; 20 acciones que se mueven en el premercado

EVAX

IDAI

INTZ

LIDR

LKCO

LUXH

MGIH

MLGO

MRBK

MTRX

NEUP

ONDS

QRHC

RVSN

SLDP

VIRX

WTBA

Descubre las acciones que lideran los movimientos en la apertura del mercado, incluyendo repuntes destacados y caídas sorprendentes.

Acciones de Evaxion Biotech (EVAX) suben alrededor del 62%; 20 acciones que se mueven en el premercado

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si Inc

WisdomTree U.S. Short Term Corporate Bond Fund

Pacer Metaurus Nasdaq 100 Dividend Multiplier 600 ETF

Marriott International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) announced plans on Monday to <a href="https://www.benzinga.com/pressreleases/25/04/n45035022/marriott-international-to-acquire-the-citizenm-brand">buy the lifestyle hotel brand</a> CitizenM.
The acquisition is expected to help Marriott expand offerings for its guests and Marriott Bonvoy loyalty members across global markets. CitizenM has 36 hotels operating in over 20 cities worldwide, including in New York, London, Paris and Rome.
CitizenM also has three additional hotels under construction, slated for completion by mid-2026. Long-term expansion is planned across Marriott's global regions.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800444/goldman-sachs-cuts-outlook-for-these-hotel-and-lodging-stocks-as-potential-recession-looms">Goldman Sachs Cuts Outlook For These Hotel And Lodging Stocks As Potential Recession Looms</a>
Under the terms of the deal, Marriott will pay $355 million for CitizenM and its related intellectual property. The CitizenM properties currently owned and leased by the seller will shift to new long-term franchise agreements managed by Marriott.
&#8220;As we continue to drive best-in-class experiences for travelers, today&#8217;s announcement builds upon Marriott&#8217;s commitment to enhance options for guests and Marriott Bonvoy members,&#8221; said&nbsp;Marriott president and CEO, Anthony Capuano.
&#8220;Marriott has a proven track record of growing acquired brands significantly by leveraging our global development ecosystem, the benefits of our industry-leading affiliation cost structure, and the power of our award-winning Marriott Bonvoy loyalty platform.&#8221;
Marriott <a href="https://www.benzinga.com/news/earnings/25/02/43629316/marriott-tops-q4-estimates-as-2025-outlook-pressures-stock">held $400 million in cash and equivalents</a> as of Dec. 31, 2024.
Future growth incentives could see the seller earn up to an additional $110 million, based on brand expansion achievements over a multi-year timeframe, starting in the fourth year after closing. 
CitizenM, established in 2008, is known for its tech-driven hospitality, artistic design, and smart use of space, offering travelers modern rooms, and rooftop terraces at an affordable price.
Pending regulatory approvals, the acquisition is expected to close in 2025. Marriott projects that this move will help drive its net room growth to nearly 5% for the full year 2025.
Price Action: MAR shares traded higher by 1.75% at $240.34 at last check Monday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45011035/meta-booz-allen-launch-space-llama-ai-system-for-space-station-operations">Meta, Booz Allen Launch &#8216;Space Llama&#8217; AI System For Space Station Operations</a></li>
</ul>
Image: Shutterstock

News

General

Marriott Bets $355M On Trendy CitizenM Hotels To Woo Modern Travelers

Wells Fargo analyst Steven Cahall maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Overweight and lowers the price target from $129 to $93.

Price Target

Analyst Ratings

ROKU

Wells Fargo Maintains Overweight on Roku, Lowers Price Target to $93

JMP Securities analyst Constantine Davides reiterates Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) from Market Perform to Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on Agilon Healthto Market Perform

Wells Fargo analyst Steven Cahall maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Equal-Weight and raises the price target from $380 to $400.

CHTR

Wells Fargo Maintains Equal-Weight on Charter Communications, Raises Price Target to $400

Wells Fargo analyst Christian Wetherbee maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Equal-Weight and lowers the price target from $400 to $260.

SAIA

Wells Fargo Maintains Equal-Weight on Saia, Lowers Price Target to $260

Wells Fargo analyst Matthew Akers maintains CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) with a Overweight and raises the price target from $438 to $513.

CACI

Wells Fargo Maintains Overweight on CACI International, Raises Price Target to $513

Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Overweight and maintains $75 price target.

CGON

Cantor Fitzgerald Reiterates Overweight on CG Oncology, Maintains $75 Price Target

Wells Fargo analyst Finian O'Shea maintains TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) with a Underweight and lowers the price target from $6.5 to $5.5.

TPVG

Wells Fargo Maintains Underweight on TriplePoint Venture Gwth, Lowers Price Target to $5.5

Wells Fargo analyst Finian O'Shea maintains Trinity Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) with a Underweight and lowers the price target from $14 to $13.

TRIN

Wells Fargo Maintains Underweight on Trinity Cap, Lowers Price Target to $13

Wells Fargo analyst Finian O'Shea maintains Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) with a Overweight and lowers the price target from $23 to $22.

TSLX

Wells Fargo Maintains Overweight on Sixth Street Specialty, Lowers Price Target to $22

ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) has outperformed the market over the past 5 years by 11.13% on an annualized basis producing an average annual return of 25.36%. Currently, ONEOK has a market capitalization of $54.44 billion. 
Buying $1000 In OKE: If an investor had bought $1000 of OKE stock 5 years ago, it would be worth $2,890.41 today based on a price of $87.19 for OKE at the time of writing.
<h3>ONEOK's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745849711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Wells Fargo analyst Finian O'Shea maintains SLR Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRC#NASDAQ">SLRC</a>) with a Underweight and lowers the price target from $13 to $12.

SLRC

Wells Fargo Maintains Underweight on SLR Inv, Lowers Price Target to $12

Wells Fargo analyst Finian O'Shea maintains Runway Growth Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) with a Overweight and lowers the price target from $12 to $10.

RWAY

Wells Fargo Maintains Overweight on Runway Growth Finance, Lowers Price Target to $10

Wells Fargo analyst Finian O'Shea maintains Prospect Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSEC#NASDAQ">PSEC</a>) with a Underweight and lowers the price target from $4 to $3.5.

PSEC

Wells Fargo Maintains Underweight on Prospect Capital, Lowers Price Target to $3.5

Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Overweight and maintains $7 price target.

TSHA

Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target

&ndash; CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab &ndash;
&ndash; Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab &ndash;
&ndash; A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026&ndash;
&ndash; Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time&ndash;
REDWOOD CITY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.&nbsp;((&quot;Coherus, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>), today announced data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) evaluating two pharmacologically active doses of CHS-114 for dose optimization. These data are being presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.

CHRS

Coherus Biosciences Presents Data From Ongoing Phase 1 Clinical Trial Evaluating CHS-114 Shows Clinical Efficacy And Proof Of Mechanism In HNSCC In Combination With Toripalimab

Wells Fargo analyst Finian O'Shea maintains Oaktree Specialty Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCSL#NASDAQ">OCSL</a>) with a Equal-Weight and lowers the price target from $15 to $14.

OCSL

Wells Fargo Maintains Equal-Weight on Oaktree Specialty Lending, Lowers Price Target to $14

Wells Fargo analyst Finian O'Shea maintains Nuveen Churchill Direct (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCDL#NYSE">NCDL</a>) with a Equal-Weight and lowers the price target from $17 to $15.

NCDL

Wells Fargo Maintains Equal-Weight on Nuveen Churchill Direct, Lowers Price Target to $15

Wells Fargo analyst Finian O'Shea maintains New Mountain Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMFC#NASDAQ">NMFC</a>) with a Equal-Weight and lowers the price target from $11 to $10.

NMFC

Wells Fargo Maintains Equal-Weight on New Mountain Finance, Lowers Price Target to $10

<ul>
<li>Six of the top policy groups representing the U.S. automotive industry sent a letter to Trump administration officials, asking them to reconsider the 25% tariffs on auto parts</li>
<li>The letter says that many auto suppliers in the U.S.  are already "in distress," and that the tariffs could put the entire industry in jeopardy</li>
<li>Trump has said that he is looking for ways to help "some of the car companies," although what form that assistance may take is still unclear</li>
</ul>
Six of the top policy groups representing the U.S. automotive industry sent a letter to officials in the Trump administration urging them to reconsider tariffs on the industry on Tuesday.
Earlier this month, President Donald Trump announced 25% tariffs on auto parts. The levies are set to take effect on Saturday, although there has been discussion of exemptions.&nbsp;
In the letter, the groups say that many auto suppliers who are already "in distress" won't be able to afford the additional cost increases. If the tariffs go forward as planned, experts warn that automotive production in the country would be in jeopardy.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
The letter, which is addressed to Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick and U.S. Trade Representative Jamieson Greer, reads, in part, according to Reuters, "Most auto suppliers are not capitalized for an abrupt tariff induced disruption. Many are already in distress and will face production stoppages, layoffs and bankruptcy. It only takes the failure of one supplier to lead to a shutdown of an automaker's production line. When this happens, as it did during the pandemic, all suppliers are impacted, and workers will lose their jobs."
The letter is signed by the heads of the Alliance for Automotive Innovation, American International Automobile Dealers Association, Autos Drive America, vehicle suppliers association MEMA, National Automobile Dealers Association, and American Automotive Policy Council. According to the groups, they represent the country's No. 1 manufacturing sector, and that the automotive industry provides 10 million jobs in all 50 states and contributes $1.2 trillion into the economy each year.&nbsp;
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
The groups seem to have hope that their pleas won't fall on deaf ears. "President Trump has indicated an openness to reconsidering the administration's 25% tariffs on imported automotive parts – similar to the tariff relief recently approved for consumer electronics and semiconductors. That would be a positive development and welcome relief," another section of the letter reads, according to <a href="https://www.cnbc.com/2025/04/22/auto-groups-lobby-trump-administration-against-parts-tariffs.html">CNBC</a>.&nbsp;
Trump has previously talked about being willing to help some of the car companies as they work on moving production.
"I'm looking for something to help some of the car companies, where they're switching to parts that were made in Canada, Mexico and other places, and they need a little bit of time because they're going to make them here… But they need a little bit of time, so I'm talking about things like that,' <a href="https://www.youtube.com/watch?v=8yERLi7elEs">Trump told reporters</a> on April 14.
CNBC reports that the auto groups' letter concludes with, "We support more manufacturing and additional supply chains that run through the United States, but it is not possible to reroute global supply chains overnight or even in months. This will take time."
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
Image: Shutterstock

Personal Finance

Auto Groups Unite To Lobby Against Trump, Say Many Suppliers Are Already 'In Distress'

Press Releases

Preprint from Northwestern University Highlights Complementary Proteomic Analysis of Interleukin-6 Using Next-Generation Protein Sequencing™ and Mass Spectrometry

Comments

Quantum-Si

Noticias

Últimas noticias sobre Quantum-Si (NASDAQ:QSI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL